Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

11-15 of 58 results for all trials

Sort by:

Filter by

Therapeutic category

Trial status

VX18-121-101 Safety and Efficacy of VX-121 combination therapy in CF

The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis.

Phase II
  • Trial Reference Number

    113399

  • Age

    18+

  • Trial status

    Closed to recruitment

  • Therapeutic category

    Restore CFTR Function

High Flow Nasal Therapy during exercise in CF

High flow nasal therapy (HFNT) is a way to deliver a mixture of air and oxygen at higher flows compared to standard oxygen therapy. It has been shown to improve oxygenation, reduce breathlessness and breathing rate, and is quite comfortable. Recently HFNT has been shown to improve exercise capacity and tolerance in patients with other lung diseases. HFNT is routinely used in clinical practice in patients with CF who present acutely unwell during hospital admissions. We believe that HFNT could be used by patients with CF during exercise in order to improve their tolerance, lengthen their exercise sessions, and allow them to be less symptomatic. We propose an initial, small-scale pilot study to assess the feasibility of a larger trial to assess efficacy. The study aims to enrol 20 patients with severe lung disease, during a hospital admission. On top of their routine 6-minute walking test, patients will be asked to have a repeated test on HFNT and to fill in a questionnaire on their physical activity. As exploratory outcomes, we will measure distance walked during the tests, oxygen and carbon dioxide levels, breathing rate, and time to recover to baseline. Patients will be asked to rate their comfort and their breathlessness.

Read more Not Applicable
  • Trial Reference Number

    121917

  • Age

    18+

  • Trial status

    Open to recruitment

  • Therapeutic category

    Other

Parameters to assess Response to Intra-Venous Antibiotic Treatment for pulmonary Exacerbations in Cystic Fibrosis

Acute changes in respiratory signs and symptoms termed Pulmonary Exacerbations require treatment with intravenous antibiotics and hospital admission. These episodes cause substantial disruption to people's lives and impact on lung function, quality of life and lifespan. Current treatment regimes require improvement but further study is needed to identify who might benefit from a different approach. This observational study aims to assess if multi-dimensional measurements taken during treatment correspond with later treatment response. This may allow us to personalise treatment more effectively in the future and to better understand how individuals respond to treatment. As yet there is no model for predicting how patients with CF will respond to IV antibiotic treatment- other than clinical judgement and lung function response.This is due to lack of robust measures to identify clinical response at the time of treatment and safely predict later clinical outcomes. The heterogeneity of the 21st Century CF population means a multi-dimensional composite measure is needed. This study has therefore been designed to provide an overall picture of people's response including clinical, biochemical and patient related outcome measures. Using multi-dimensional assessment we hope the measures assessed in this study will give a better picture of how people feel and how they respond to treatment.

Read more Not Applicable
  • Trial Reference Number

    84648

  • Age

    18+

  • Trial status

    Closed to recruitment

  • Therapeutic category

    Other

Intravenous iron in adults with cystic fibrosis

Adults with cystic fibrosis often have low iron levels (iron deficiency). This is partly due to poor absorption of iron from the gut, and partly to the trapping of iron within cells of the immune system during periods of infection. Unfortunately, iron tablets are often ineffective in this setting, and may cause significant side effects in patients with cystic fibrosis. In other patient groups, intravenous iron is used routinely to correct iron deficiency. In these patients it has been shown to be safe, and to improve energy levels, exercise tolerance, cognitive function and quality of life, even in the absence of anaemia. Recent research suggests that iron may be particularly beneficial in patients with heart and lung disease.Despite these possible benefits, IV iron is rarely used in patients with CF, due in part to concerns about encouraging the growth of bacterial in the lungs. Iron deficiency therefore often goes untreated. However, since no clinical trials have examined the use of IV iron in CF patients to date, the risks and benefits remain uncertain. We plan to undertake a small pilot study examining the effects of IV iron in 20 adults with CF and low iron levels. We will primarily assess whether intravenous iron is safe and effective at treating iron deficiency in this group, but will also study various other clinical parameters, to guide the design of future larger studies.

Read more Phase IV
  • Trial Reference Number

    110427

  • Age

    18+

  • Trial status

    Open to recruitment

  • Therapeutic category

    Nutritional-GI

A dose finding study of OligoG in patients with Cystic Fibrosis

OligoG is a small sugar molecule that comes from seaweed, harvested off the coast of Norway. Studies indicate that OligoG may make CF mucus less sticky, and it may also help antibiotics to combat infections. Although OligoG has been tested and found to be safe in about 130 CF patients, more research is needed to find the best dose and to study the effect of longer term use. OligoG is given as a dry powder for inhalation. Ten capsules are to be taken twice daily. During this study patients may take their other usual medications in addition to OligoG. Part 1 will be a three month long study to find the best of three different doses. Each patient will be given one of three different OligoG doses, or a placebo (placebo is a product that looks like the test medication, but it does not contain any OligoG). This means that 3 of 4 patients will receive active medication You will be asked to visit the clinic 7 times in Part 1.Part 2 is designed to assess the efficacy, safety and tolerability of the chosen dose of OligoG compared to placebo following 26 weeks of treatment. The patients will take OligoG or placebo twice daily for 26 weeks. Half of the patients will receive active drug. You will be asked to visit the clinic 10 times in Part 2.

Read more Phase II
  • Trial Reference Number

    106614

  • Trial status

    Project in Setup

  • Therapeutic category

    Anti-Infective

11-15 of 58 results for all trials